Interleukin-1 inhibition for combination treatment of pancreatic cancer cachexia
AssigneeCedars-Sinai Medical Center
InventorAndrew Hendifar
Life of this patent
Estimating the term…
Abstract
A composition for IL-1 inhibition in combination with cancer therapies (e.g., chemotherapeutics including chemotherapy protective drugs) is provided for use in treating pancreatic cancer cachexia in patients, so as to reduce weight loss and improve the quality of life and survival of the patients. In one embodiment, the IL-1 inhibitor is an antibody, such as bermekimab, anakinra, canakinumab, gevokizumab, or rilonacept, administered simultaneously or sequentially with iritenocan, 5-fluorouracil and folinic acid to a pancreatic cancer patient.
Claims18
A method for treating, inhibiting and/or reducing the severity of cancer cachexia in a subject in need thereof comprising administering an effective amount of an inhibitor of IL-1 pathway to the subject, wherein the inhibitor comprises an anti-IL-1βantibody or an IL-1β-binding fragment thereof.
A method for treating, inhibiting and/or reducing the severity of cancer in a subject in need thereof comprising administering an effective amount of an inhibitor of IL-1 pathway, wherein the inhibitor comprises an anti-IL-1β antibody or an IL-1β-binding fragment thereof.
16-20. (canceled)
Dependencies are inferred from the claim text.